{
  "query": "approved free progression cancer",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT01908556",
          "briefTitle": "Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-02"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients."
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3545,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04425681",
          "briefTitle": "Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leptomeningeal Metastasis", "Non-small Cell Lung Cancer", "EGFR Activating Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07284069",
          "briefTitle": "Senicapoc and Perampanel for Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02154737",
          "briefTitle": "Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2020-09-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06348134",
          "briefTitle": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "HER2-positive Breast Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01603004",
          "briefTitle": "Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-06-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Neuroendocrine Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02393209",
          "briefTitle": "Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06495164",
          "briefTitle": "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Malignant Neoplasm of Breast"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04533321",
          "briefTitle": "A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06182306",
          "briefTitle": "Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Triple Negative Breast Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05842187",
          "briefTitle": "In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Cancer", "Gastric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03161223",
          "briefTitle": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, T-Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01952730",
          "briefTitle": "Pilot Study of GVAX in Colorectal Cancer Cells"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06885671",
          "briefTitle": "Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Early Stage Breast Cancer (Stage 1-3)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05770037",
          "briefTitle": "DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Haematological Malignancy", "Malignant Neoplasm", "Lymphoproliferative Disorders", "Neoplasms by Histologic Type", "Neoplasms by Site", "Cancer", "Anaplastic Large Cell Lymphoma", "Lymphoma", "Renal Cell Carcinoma", "Neuroblastoma", "Solid Tumour"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03520075",
          "briefTitle": "Study of ASTX029 in Subjects With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumor, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06875128",
          "briefTitle": "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer in the Liver"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00804336",
          "briefTitle": "Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-10"
          },
          "completionDateStruct": {
            "date": "2015-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumor", "Carcinoid Tumor", "Pancreatic Neuroendocrine Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03356912",
          "briefTitle": "CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Castration-resistant Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 220,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02652871",
          "briefTitle": "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03734198",
          "briefTitle": "Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Chronic Lymphocytic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02093000",
          "briefTitle": "A Study Examining Maintenance Bevacizumab (AvastinÂ®) Monotherapy in Participants With Advanced Lung Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Adenocarcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 201,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04909034",
          "briefTitle": "A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC Stage IIIB~IV"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02294357",
          "briefTitle": "Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12"
          },
          "completionDateStruct": {
            "date": "2020-09-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02155465",
          "briefTitle": "Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05894239",
          "briefTitle": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-12-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 230,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03264066",
          "briefTitle": "A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-06-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 87,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07060001",
          "briefTitle": "Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukaemia (AML)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 112,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06185751",
          "briefTitle": "Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2040-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06826677",
          "briefTitle": "REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05078775",
          "briefTitle": "Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Pancreatic Adenocarcinoma", "Locally Advanced Unresectable Pancreatic Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05902169",
          "briefTitle": "Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Recurrent Glioblastoma", "GBM"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 560,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00916669",
          "briefTitle": "A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-07"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01904253",
          "briefTitle": "A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer (SCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04814095",
          "briefTitle": "PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04739202",
          "briefTitle": "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Adenocarcinoma", "Advanced Gastric Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06846437",
          "briefTitle": "JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 228,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03323151",
          "briefTitle": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mantle-Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06106802",
          "briefTitle": "Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06690528",
          "briefTitle": "Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 56,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03713580",
          "briefTitle": "Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05113290",
          "briefTitle": "Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05815173",
          "briefTitle": "Ladarixin With Sotorasib in Advanced NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01716208",
          "briefTitle": "Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01501370",
          "briefTitle": "Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01"
          },
          "completionDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04973670",
          "briefTitle": "Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "ARDS"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 238,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04534725",
          "briefTitle": "COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Covid19", "Respiratory Viral Infection"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 441,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03161756",
          "briefTitle": "Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma Stage Iv", "Melanoma Stage Iii", "Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01185509",
          "briefTitle": "Trastuzumab and Vinorelbine in Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Metastatic Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06908993",
          "briefTitle": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Non Small Cell Lung Cancer", "MET Exon 14 Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 133,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03801304",
          "briefTitle": "Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-02-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06545955",
          "briefTitle": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06878664",
          "briefTitle": "Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 166,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06050512",
          "briefTitle": "Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed and Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03258021",
          "briefTitle": "TTFields In GErmany in Routine Clinical Care"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 710,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07082452",
          "briefTitle": "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment NaÃ¯ve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2031-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia, B-Cell, Chronic", "Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 262,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04348032",
          "briefTitle": "Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-resistant Recurrent Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02793765",
          "briefTitle": "Docetaxel Followed by Provenge in Metastatic Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-12"
          },
          "completionDateStruct": {
            "date": "2021-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00327600",
          "briefTitle": "Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07"
          },
          "completionDateStruct": {
            "date": "2007-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Malignant Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00936936",
          "briefTitle": "High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-06-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Testicular Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 64,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05498155",
          "briefTitle": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00693992",
          "briefTitle": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06177496",
          "briefTitle": "Influence of Sarcopenia in Hepatocellular Carcinoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcopenia"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05308966",
          "briefTitle": "Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-08-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Malignant Pleural Mesothelioma", "Unresectable Malignant Neoplasm"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 204,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02837029",
          "briefTitle": "Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07"
          },
          "completionDateStruct": {
            "date": "2020-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IIIA Hepatocellular Carcinoma", "Stage IIIB Hepatocellular Carcinoma", "Stage IIIC Hepatocellular Carcinoma", "Stage IVA Hepatocellular Carcinoma", "Stage IVB Hepatocellular Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05071846",
          "briefTitle": "MVX-ONCO-2 in Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Solid Tumor, Adult"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05057702",
          "briefTitle": "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Medulloblastoma", "Medulloblastoma, Childhood", "Medulloblastoma Recurrent", "Ependymoma", "Ependymoma Malignant", "Ependymoma of Brain"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04242173",
          "briefTitle": "Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cutaneous Squamous Cell Carcinoma", "Cutaneous Squamous Cell Carcinoma of the Head and Neck"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06138769",
          "briefTitle": "Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01287520",
          "briefTitle": "A Study of LY2090314 in Patients With Advanced or Metastatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-11"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02614794",
          "briefTitle": "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-08-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "HER2 Positive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 612,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04402333",
          "briefTitle": "Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-10-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Ovarian Neoplasm", "Ovarian Neoplasm Epithelial", "Fallopian Tube Cancer", "Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06626516",
          "briefTitle": "Tebentafusp-tebn With LDT in Metastatic UM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Uveal Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 109,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01761747",
          "briefTitle": "Ponatinib for Squamous Cell Lung and Head and Neck Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer, Head and Neck Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05874193",
          "briefTitle": "A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed/Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06892678",
          "briefTitle": "DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Osteosarcoma Recurrent", "Ewing's Tumor Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "39 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07226999",
          "briefTitle": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-17",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2034-03-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer (SCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 550,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04892849",
          "briefTitle": "Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HNSCC", "NSCLC", "Esophageal Cancer", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma of the Skin", "Small Cell Bronchial Carcinomas"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02188368",
          "briefTitle": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00473889",
          "briefTitle": "A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-05"
          },
          "completionDateStruct": {
            "date": "2008-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stage IIIB or IV Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 253,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06841679",
          "briefTitle": "Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric or Gastroesophageal Junction Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 778,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05361720",
          "briefTitle": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04874025",
          "briefTitle": "Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 815,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00733850",
          "briefTitle": "Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-08"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 85,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05036291",
          "briefTitle": "A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06891560",
          "briefTitle": "A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Adenoid Cystic Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06339424",
          "briefTitle": "Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04163289",
          "briefTitle": "Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02139397",
          "briefTitle": "Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroblastoma Recurrent"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01726582",
          "briefTitle": "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2022-04-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 229,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01892397",
          "briefTitle": "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Brain Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00848510",
          "briefTitle": "EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-02"
          },
          "completionDateStruct": {
            "date": "2013-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal and Ovarian Cancer Patients With Liver Metastases"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06726148",
          "briefTitle": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 280,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03811652",
          "briefTitle": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-12-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non Small Cell Lung Cancer Squamous (NSCLC-Sq)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Small Cell Lung Cancer (SCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "101 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02783885",
          "briefTitle": "Clinical Utilization of Newly Approved Oncology Medications"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05"
          },
          "completionDateStruct": {
            "date": "2020-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07225621",
          "briefTitle": "Adjuvant Temozolomide Â± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "GBM"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 103,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02795858",
          "briefTitle": "A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-06-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06999707",
          "briefTitle": "Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HCC - Hepatocellular Carcinoma", "Tremelimumab", "Durvalumab", "Radiotherapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06954584",
          "briefTitle": "Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 424,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03556384",
          "briefTitle": "Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastrointestinal Stromal Tumors", "Sdh", "GIST", "Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT06238843",
          "briefTitle": "A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 450,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03219333",
          "briefTitle": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 219,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04779489",
          "briefTitle": "Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-09-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01402284",
          "briefTitle": "Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-09-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03434158",
          "briefTitle": "Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02347852",
          "briefTitle": "Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-01-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-09-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02283749",
          "briefTitle": "BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09"
          },
          "completionDateStruct": {
            "date": "2018-11-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer With Bone Metastatses"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05869097",
          "briefTitle": "Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-04-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Colorectal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04022213",
          "briefTitle": "A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Desmoplastic Small Round Cell Tumor", "Peritoneal Cancer", "Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06012435",
          "briefTitle": "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 703,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04435691",
          "briefTitle": "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 110,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06107413",
          "briefTitle": "Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unresectable Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 280,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01572480",
          "briefTitle": "Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-05-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02164240",
          "briefTitle": "Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Stromal Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01282476",
          "briefTitle": "Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Diffuse Large B Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02396368",
          "briefTitle": "A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-03"
          },
          "completionDateStruct": {
            "date": "2017-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01425008",
          "briefTitle": "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Metastatic Melanoma", "Solid Tumor", "Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 149,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03525782",
          "briefTitle": "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Neoplasm Malignant", "Non-small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04751877",
          "briefTitle": "Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (â¥ 65; < 80 Years)."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08-17",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 270,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years",
          "maximumAge": "79 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02541903",
          "briefTitle": "Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10"
          },
          "completionDateStruct": {
            "date": "2020-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Penile Squamous Cell Carcinoma (PSCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05863195",
          "briefTitle": "Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Colorectal Carcinoma", "Metastatic Malignant Neoplasm in the Liver", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 408,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07272512",
          "briefTitle": "Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11-29",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumors", "Neuroendocrine Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 350,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04401995",
          "briefTitle": "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05108870",
          "briefTitle": "TheraTÂ® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Papilloma Virus", "HPV", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Head and Neck Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 98,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01760694",
          "briefTitle": "Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01"
          },
          "completionDateStruct": {
            "date": "2014-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05144529",
          "briefTitle": "A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-NaÃ¯ve Patients With Metastatic NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05683977",
          "briefTitle": "A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 254,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05578326",
          "briefTitle": "Study of Trilaciclib and Lurbinectidin"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Cancer", "Small-cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04982926",
          "briefTitle": "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-09-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor", "Glioblastoma", "Non-small Cell Lung Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04107168",
          "briefTitle": "Microbiome Immunotherapy Toxicity and Response Evaluation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Renal Cancer", "Lung Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1800,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03890068",
          "briefTitle": "Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06169410",
          "briefTitle": "Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02525757",
          "briefTitle": "MPDL3280A With Chemoradiation for Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Cancer", "Non-Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06294548",
          "briefTitle": "A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07274774",
          "briefTitle": "SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-11-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 184,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06199297",
          "briefTitle": "Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 188,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06619236",
          "briefTitle": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-resistant Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 530,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05099471",
          "briefTitle": "Efficacy of Venetoclax in Combination With Rituximab in WaldenstrÃ¶m's Macroglobulinemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Waldenstrom Macroglobulinemia", "Treatment Naive"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03296163",
          "briefTitle": "A Study Comparing MB02 and AvastinÂ® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 627,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02638090",
          "briefTitle": "Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Cancer", "Non-small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03574220",
          "briefTitle": "Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05098405",
          "briefTitle": "First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Malignant Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02047253",
          "briefTitle": "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-07-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Castration-resistant Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05662397",
          "briefTitle": "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor, Adult", "Relapsed Cancer", "Refractory Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 77,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03553004",
          "briefTitle": "Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-02-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03121352",
          "briefTitle": "Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00869999",
          "briefTitle": "Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2011-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Diffuse Large B-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04051606",
          "briefTitle": "Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-03-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06508606",
          "briefTitle": "AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06896916",
          "briefTitle": "Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 135,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03213964",
          "briefTitle": "Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-03-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02288936",
          "briefTitle": "Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hormone-refractory Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 98,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06698744",
          "briefTitle": "UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05346536",
          "briefTitle": "Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Cancer", "Circulating Tumor Cell"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04577807",
          "briefTitle": "LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01688999",
          "briefTitle": "Cabozantinib for Advanced Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-09-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-09-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Urothelial Carcinoma", "Urethral Neoplasms", "Urinary Bladder Neoplasms", "Kidney Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 69,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03782207",
          "briefTitle": "A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Urothelial Carcinoma", "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Hepatocellular Carcinoma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2756,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00047879",
          "briefTitle": "Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-10"
          },
          "completionDateStruct": {
            "date": "2009-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 7,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06113809",
          "briefTitle": "Palbociclib and Pembrolizumab in Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01838512",
          "briefTitle": "Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2555,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01857934",
          "briefTitle": "Therapy for Children With Advanced Stage Neuroblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 153,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06548919",
          "briefTitle": "Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["ESR1 Gene Mutation", "Advanced Breast Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 450,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04327700",
          "briefTitle": "Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04329949",
          "briefTitle": "Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-03-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02983604",
          "briefTitle": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-07-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Estrogen Receptor Positive HER2- Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02584647",
          "briefTitle": "PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-11-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Sarcoma", "Malignant Peripheral Nerve Sheath Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01540058",
          "briefTitle": "Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-03-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-08-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms, Unknown Primary"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 243,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06630221",
          "briefTitle": "Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07155187",
          "briefTitle": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 430,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07293754",
          "briefTitle": "An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-04-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Malignant Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06422403",
          "briefTitle": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Hepatocellular", "Gastric Adenocarcinoma", "GastroEsophageal Cancer", "Oesophageal Cancer", "Non-small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 360,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00895661",
          "briefTitle": "High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["B-cell Lymphoma", "Indolent B-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03104270",
          "briefTitle": "Combination Study for High Risk Multiple Myeloma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-03-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-01-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01616186",
          "briefTitle": "Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07"
          },
          "completionDateStruct": {
            "date": "2016-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Metastatic Malignant Neoplasm"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04589039",
          "briefTitle": "A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-03-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 662,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04180761",
          "briefTitle": "Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-11",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2022-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06445972",
          "briefTitle": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-10-27",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03815474",
          "briefTitle": "Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcoma, Soft Tissue"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05670054",
          "briefTitle": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Stage IV"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05011188",
          "briefTitle": "FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06999694",
          "briefTitle": "Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HCC - Hepatocellular Carcinoma", "Durvalumab", "Tremelimumab", "Proton Radiotherapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04006119",
          "briefTitle": "Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-08-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02708667",
          "briefTitle": "An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-09"
          },
          "completionDateStruct": {
            "date": "2016-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06481904",
          "briefTitle": "Registry for Stage 2 Type 1 Diabetes"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2037-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Type 1 Diabetes"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04735068",
          "briefTitle": "Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Small Cell Lung Cancer", "KRAS Mutation-Related Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03029403",
          "briefTitle": "Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-02-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-04-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03740256",
          "briefTitle": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2038-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Head and Neck Squamous Cell Carcinoma", "Cancer of the Salivary Gland", "Lung Cancer", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Colorectal Cancer", "Pancreatic Adenocarcinoma", "Solid Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01777594",
          "briefTitle": "Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01"
          },
          "completionDateStruct": {
            "date": "2015-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Adult Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02133742",
          "briefTitle": "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-09-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 52,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01484041",
          "briefTitle": "Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-04"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06100705",
          "briefTitle": "Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Castration-resistant Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02858895",
          "briefTitle": "Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-10-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Grade IV Astrocytoma", "Glioblastoma Multiforme", "Grade IV Glioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03283631",
          "briefTitle": "Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Glioblastoma", "Recurrent Gliosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00970502",
          "briefTitle": "Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-02"
          },
          "completionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer of the Pharynx", "Cancer of the Larynx", "Cancer of the Neck", "Paranasal Sinus Neoplasms", "Cancer of the Head"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04263480",
          "briefTitle": "Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in WaldenstrÃ¶m's Macroglobulinemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Waldenstrom Macroglobulinemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 99,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01713296",
          "briefTitle": "Pazopanib in Relapsed and Refractory Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2015-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "SCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 58,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06705686",
          "briefTitle": "Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Castration-resistant Prostate Cancer (CRPC)", "Metastatic Castration-resistant Prostate Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05609656",
          "briefTitle": "Electroporation and Immunotherapy in Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05761977",
          "briefTitle": "Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Small-cell Lung Cancer", "Extensive-stage Small-cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03554473",
          "briefTitle": "M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Carcinoma, Small Cell", "Lung Cancer", "Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT04416568",
          "briefTitle": "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-08-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Malignant Rhabdoid Tumor", "Rhabdoid Tumor of the Kidney", "Epithelioid Sarcoma", "Chordoma (Poorly Differentiated or De-differentiated)", "Atypical Teratoid/Rhabdoid Tumor", "Other INI1 Negative Tumors (With PI Approval)", "Other SMARCA4-deficient Malignant Tumors (With PI Approval)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Months",
          "maximumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01013324",
          "briefTitle": "Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-01"
          },
          "completionDateStruct": {
            "date": "2013-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Endometrial Cancer", "Endometrial Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 67,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04639986",
          "briefTitle": "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 331,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01847495",
          "briefTitle": "Evaluation of Low-dose Irinotecan and CyberknifeÂ® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-10"
          },
          "completionDateStruct": {
            "date": "2017-11-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05096286",
          "briefTitle": "Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Intracranial Metastatic Disease From Any Solid Malignancy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03081702",
          "briefTitle": "A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-07-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-08-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Platinum-resistant Epithelial Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06102525",
          "briefTitle": "A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04364620",
          "briefTitle": "AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-02-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC Stage IV"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05393791",
          "briefTitle": "Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostatic Neoplasms, Castration-Resistant"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 168,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04256018",
          "briefTitle": "Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & SÃ©zary Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-03-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Sezary Syndrome", "Mycosis Fungoides"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00864513",
          "briefTitle": "Study of Pemetrexed for Second-Line Pancreas Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-10"
          },
          "completionDateStruct": {
            "date": "2009-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreas Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06321913",
          "briefTitle": "Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06210490",
          "briefTitle": "A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Upper Urinary Tract Urothelial Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07159906",
          "briefTitle": "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-08",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Diffuse Large B-Cell Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 62,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03207555",
          "briefTitle": "Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 23,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00606008",
          "briefTitle": "A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-03"
          },
          "completionDateStruct": {
            "date": "2012-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anaplastic Astrocytoma", "Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05584111",
          "briefTitle": "Oral Administration of STC-15 in Subjects With Advanced Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cancer", "Advanced Solid Tumor", "Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04173325",
          "briefTitle": "Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Small-cell Lung Cancer", "Small Cell Lung Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07285148",
          "briefTitle": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Small Cell Lung Cancer", "EGFR Mutation", "Metastatic Lung Cancer", "MET Alteration"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 253,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05192798",
          "briefTitle": "Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple-negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 128,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05949541",
          "briefTitle": "Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Advanced Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 265,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05306340",
          "briefTitle": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 373,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05332496",
          "briefTitle": "TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 220,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06472388",
          "briefTitle": "Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumors", "Progression", "Neuroendocrine Tumor Grade 1", "Neuroendocrine Tumor Grade 2", "Neuroendocrine Tumor of Pancreas", "Neuroendocrine Tumor of the Lung", "Neuroendocrine Tumor Carcinoid"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07294430",
          "briefTitle": "Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced or Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04960709",
          "briefTitle": "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Muscle Invasive Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 712,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02392871",
          "briefTitle": "Radiotherapy & Combi in Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-04-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02642406",
          "briefTitle": "Therapy Management With Nab-Paclitaxel in Daily Routine"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12"
          },
          "completionDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06890884",
          "briefTitle": "A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-12-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large B-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 594,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04004338",
          "briefTitle": "Carfilzomib in Combination for the Treatment of RR MM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-04-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Relapse Multiple Myeloma", "Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 300,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06225427",
          "briefTitle": "Gilteritinib for the Treatment of ALK NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06541262",
          "briefTitle": "Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2035-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroblastoma Recurrent", "Ewing's Sarcoma Recurrent", "Osteosarcoma Recurrent", "Rhabdomyosarcoma Recurrent", "Liposarcoma Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 104,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07284186",
          "briefTitle": "First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Metastatic Solid Tumor", "Non-Small Cell Lung Carcinoma", "Esophageal Adenocarcinoma", "SMARCA4 Mutation", "Gastroesophageal Junction Squamous Cell Carcinoma", "Advanced Solid Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 155,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00642018",
          "briefTitle": "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-03"
          },
          "completionDateStruct": {
            "date": "2012-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 154,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05265013",
          "briefTitle": "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-03-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02135133",
          "briefTitle": "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06"
          },
          "completionDateStruct": {
            "date": "2020-10-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03516708",
          "briefTitle": "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-08-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 49,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01517243",
          "briefTitle": "Phase II Study of Alternating Sunitinib and Temsirolimus"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-09-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-08-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04634552",
          "briefTitle": "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hematological Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 510,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00215982",
          "briefTitle": "Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-12"
          },
          "completionDateStruct": {
            "date": "2007-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06564324",
          "briefTitle": "A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 138,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01580696",
          "briefTitle": "Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-04"
          },
          "completionDateStruct": {
            "date": "2016-07-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Endometrial Cancer", "Fallopian Cancer", "Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01419197",
          "briefTitle": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 602,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00418496",
          "briefTitle": "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-11-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Renal Cancer", "Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06024603",
          "briefTitle": "Individualized Treatments in Adults With Relapsed/Refractory Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory Cancer", "Relapsed Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05977036",
          "briefTitle": "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Breast Cancer", "Unresectable Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01059071",
          "briefTitle": "Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02"
          },
          "completionDateStruct": {
            "date": "2015-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04683965",
          "briefTitle": "Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04341181",
          "briefTitle": "ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-08-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Tumors", "Neoplasms", "Neoplasia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 300,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01551251",
          "briefTitle": "Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-01"
          },
          "completionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Nonsmall Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04042714",
          "briefTitle": "TAS-102 in Extrapulmonary Neuroendocrine Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "High-grade Extra Pulmonary Neuroendocrine Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06169371",
          "briefTitle": "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04547452",
          "briefTitle": "Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IV HCC", "Immunotherapy", "SBRT"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00394433",
          "briefTitle": "Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-09"
          },
          "completionDateStruct": {
            "date": "2016-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophageal Cancer", "Stomach Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05842525",
          "briefTitle": "Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 42,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03632135",
          "briefTitle": "Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 78,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05745350",
          "briefTitle": "First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer Extensive Stage"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06576635",
          "briefTitle": "LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03803397",
          "briefTitle": "Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01548170",
          "briefTitle": "To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-04"
          },
          "completionDateStruct": {
            "date": "2011-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "35 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06305754",
          "briefTitle": "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-06-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer (NSCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 520,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02793219",
          "briefTitle": "Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06161532",
          "briefTitle": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C..."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Small Cell Carcinoma of the Bladder", "Small Cell Carcinoma of the Urinary Tract", "Squamous Cell Carcinoma of the Bladder", "Squamous Cell Carcinoma of the Urinary Tract", "Primary Adenocarcinoma of the Bladder", "Primary Adenocarcinoma of the Urinary Tract", "Renal Medullary Carcinoma", "Squamous Cell Carcinoma of the Penis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02812667",
          "briefTitle": "Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06842030",
          "briefTitle": "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-04-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Personalized Medicine", "Oligometastatic Disease", "Feasibility"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03673332",
          "briefTitle": "Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced or Metastatic Melanoma", "Advanced or Metastatic NSCLC"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02015728",
          "briefTitle": "Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-12"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Childhood Brain Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Month",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01473901",
          "briefTitle": "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02939651",
          "briefTitle": "A Study of Pembrolizumab in Patients With Neuroendocrine Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01950195",
          "briefTitle": "SRS (Stereotactic Radiosurgery) Plus Ipilimumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-09"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Newly Diagnosed Melanoma Metastases in the Brain and Spine"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07121322",
          "briefTitle": "Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory Germ Cell Tumors", "Dornase Alfa"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06760637",
          "briefTitle": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2037-12-29",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1020,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01858441",
          "briefTitle": "Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04"
          },
          "completionDateStruct": {
            "date": "2020-12-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pharmacogenetic Study"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06694454",
          "briefTitle": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-06",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2034-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-small Cell Lung Cancer (NSCLC)", "Carcinoma, Non-Small Cell Lung", "Non-Small Cell Lung Carcinoma", "Non Small Cell Lung Cancer", "Non Small Cell Lung Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05518994",
          "briefTitle": "Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Astrocytoma of Brain"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03494296",
          "briefTitle": "A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04926324",
          "briefTitle": "A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Rectal Neoplasms", "Rectal Neoplasm Malignant"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01821859",
          "briefTitle": "Abraxane/Bevacizumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-01"
          },
          "completionDateStruct": {
            "date": "2011-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Peritoneal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03076372",
          "briefTitle": "A Study Evaluating MM-310 in Patients With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumors", "Urothelial Carcinoma", "Gastric Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Prostate Adenocarcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Endometrial Carcinoma", "Soft Tissue Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03101566",
          "briefTitle": "Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Biliary Tract Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 75,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00634751",
          "briefTitle": "CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-02"
          },
          "completionDateStruct": {
            "date": "2010-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Neoplasms", "Bile Duct Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05286229",
          "briefTitle": "A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed/Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06402695",
          "briefTitle": "Observational Study on GEP-and Pulm-NET Treated at FPG"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Neuroendocrine Tumors", "Gep Net", "Pulmonary Neuroendocrine Neoplasm"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 650,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04531228",
          "briefTitle": "TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Carcinoma", "Transarterial Chemoembolization"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "17 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03057509",
          "briefTitle": "A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Bowel Carcinoid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02987998",
          "briefTitle": "Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stage IIIA Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01289821",
          "briefTitle": "First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-02"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03190616",
          "briefTitle": "Apatinib in Refractory Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-12-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00706706",
          "briefTitle": "Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-07"
          },
          "completionDateStruct": {
            "date": "2011-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Renal Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 105,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04104893",
          "briefTitle": "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Castration Resistant Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00268593",
          "briefTitle": "Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-08"
          },
          "completionDateStruct": {
            "date": "2008-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05256290",
          "briefTitle": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Squamous Lung Cancer", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "NSCLC", "Advanced Lung Carcinoma", "Epidermal Growth Factor Receptor C797S", "Epidermal Growth Factor Receptor G719X", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR-TKI Resistant Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03326674",
          "briefTitle": "Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 685,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06084481",
          "briefTitle": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 285,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06821542",
          "briefTitle": "A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Graft-versus-host-disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01642186",
          "briefTitle": "Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-07-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Fibrolamellar Carcinoma", "Fibrolamellar Liver Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05184842",
          "briefTitle": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["MDS", "AML", "CMML"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 85,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01131169",
          "briefTitle": "Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-05-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "72 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07052305",
          "briefTitle": "NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-YescartaÂ® (Axicabtagene Ciloleucel) or Post-BreyanziÂ® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-28",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Large B-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02928120",
          "briefTitle": "Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02"
          },
          "completionDateStruct": {
            "date": "2018-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Neoplasms", "Aberrant DNA Methylation"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 658,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ]
  }
}
